Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 67.01%1.45B | 126.78%1.48B | 131.57%1.4B | 31.84%3.52B | 60.68%1.4B | 28.48%865.33M | 7.81%651.25M | 15.83%604.8M | 23.94%2.67B | 73.11%871.5M |
| Cost of revenue | 36.06%3.04B | 25.01%2.24B | ||||||||
| Gross profit | 10.10%478.04M | 18.71%434.18M | ||||||||
| Operating expense | 65.94%1.34B | 126.64%1.36B | 134.69%1.29B | 12.01%265.04M | 70.90%1.31B | 31.42%810.34M | 7.64%599.79M | 14.73%550.1M | 24.30%236.62M | 157.71%766.37M |
| Selling and administrative expenses | ---- | ---- | ---- | 15.93%261.97M | ---- | ---- | ---- | ---- | 21.07%225.96M | ---- |
| -General and administrative expense | ---- | ---- | ---- | 15.93%261.97M | ---- | ---- | ---- | ---- | 21.07%225.96M | ---- |
| Other operating expenses | 63.65%1.35B | 126.70%1.36B | 129.52%1.3B | -71.13%3.08M | 63.46%1.32B | 33.11%825.26M | 6.96%601.39M | 16.58%564.61M | 186.05%10.66M | 152.87%807.1M |
| Total other operating income | -60.29%5.92M | 149.44%3.98M | -66.60%4.85M | -24.93%40.55M | -76.61%9.53M | 341.26%14.92M | -68.34%1.6M | 197.91%14.51M | --54.02M | --40.73M |
| Operating profit | 82.85%100.55M | 128.44%117.55M | 100.16%109.48M | 7.81%213M | -13.85%90.56M | -3.37%54.99M | 9.77%51.46M | 28.18%54.69M | 12.64%197.56M | 150.52%105.13M |
| Net non-operating interest income (expenses) | 353.41%25.95M | 312.50%5.2M | 112.12%1.39M | 148.90%10.5M | 384.19%18.67M | 195.26%5.72M | 48.26%-2.45M | -174.88%-11.45M | -417.30%-21.47M | -8.40%-6.57M |
| Non-operating interest income | 77.01%39.6M | 17.22%17.98M | 201.33%14.27M | 544.39%63.8M | 286.37%33.22M | 218.58%22.37M | 128.17%15.34M | 15.38%4.73M | 287.32%9.9M | 224.50%8.6M |
| Non-operating interest expense | -18.02%13.65M | -28.17%12.77M | -20.41%12.88M | 35.99%65.16M | -4.06%14.55M | 27.75%16.65M | 55.28%17.78M | 95.72%16.18M | 165.84%47.92M | 44.85%15.17M |
| Total other finance cost | ---- | ---- | ---- | 28.26%-11.87M | ---- | ---- | ---- | ---- | -46.17%-16.54M | ---- |
| Net investment income | -59.50%1.68M | 71.27%4.14M | ||||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | 32K | 0 | ||||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
| Income from associates and other participating interests | 5.45M | 2.86M | 2.32M | 102.11%298K | 102.06%298K | 0 | 0 | 0 | -932.29%-14.15M | -636.83%-14.46M |
| Special income (charges) | -149.84%-4.89M | -351.05%-3M | 102.31%37K | 648.24%23.84M | 104.51%1.05M | 451.90%9.81M | 700.50%1.2M | -61.62%-1.6M | 59.92%-4.35M | -5,948.37%-23.34M |
| Less:Other special charges | ---- | ---- | ---- | 41.24%-13.38M | ---- | ---- | ---- | ---- | -2,119.88%-22.78M | ---- |
| Less:Write off | 149.84%4.89M | 351.05%3M | -102.31%-37K | -138.56%-10.46M | -104.51%-1.05M | -451.90%-9.81M | -700.50%-1.2M | 61.62%1.6M | 128.36%27.13M | 3,621.69%23.34M |
| Other non-operating income (expenses) | -12.27%23.62M | 37.68%26.92M | ||||||||
| Income before tax | 80.16%127.06M | 144.23%122.62M | 171.84%113.22M | 44.70%272.96M | 82.01%110.58M | 46.59%70.53M | 18.79%50.21M | 11.02%41.65M | 2.49%188.65M | 7.90%60.76M |
| Income tax | 40.15%30.67M | 128.15%28.38M | 207.71%27.49M | 77.44%75.94M | 164.93%32.69M | 73.74%21.88M | 38.32%12.44M | 0.68%8.93M | -5.56%42.8M | 14.25%12.34M |
| Net income | 98.16%96.39M | 149.52%94.24M | 162.05%85.73M | 35.09%197.02M | 60.88%77.9M | 36.96%48.64M | 13.52%37.77M | 14.22%32.71M | 5.12%145.85M | 6.40%48.42M |
| Net income continuous operations | 98.16%96.39M | 149.52%94.24M | 162.05%85.73M | 35.09%197.02M | 60.88%77.9M | 36.96%48.64M | 13.52%37.77M | 14.22%32.71M | 5.12%145.85M | 6.40%48.42M |
| Noncontrolling interests | 479.64%12.61M | 1,039.42%10.34M | 3,128.06%10.01M | 1,270.60%10.12M | 1,131.91%8.73M | 332.60%2.18M | -512.36%-1.1M | -61.87%310K | -79.26%738K | -513.04%-846K |
| Net income attributable to the company | 80.30%83.78M | 115.84%83.89M | 133.67%75.72M | 28.80%186.91M | 40.40%69.17M | 32.71%46.47M | 17.77%38.87M | 16.44%32.4M | 7.34%145.11M | 7.93%49.27M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | 80.30%83.78M | 115.84%83.89M | 133.67%75.72M | 28.80%186.91M | 40.40%69.17M | 32.71%46.47M | 17.77%38.87M | 16.44%32.4M | 7.34%145.11M | 7.93%49.27M |
| Gross dividend payment | ||||||||||
| Basic earnings per share | 77.22%0.0638 | 114.95%0.0647 | 133.86%0.0587 | 28.89%0.145 | 40.31%0.0536 | 32.35%0.036 | 17.58%0.0301 | 16.20%0.0251 | 7.35%0.1125 | 8.22%0.0382 |
| Diluted earnings per share | 76.94%0.0637 | 113.62%0.0643 | 133.47%0.0586 | 28.89%0.145 | 40.31%0.0536 | 32.35%0.036 | 17.58%0.0301 | 16.20%0.0251 | 7.35%0.1125 | 8.22%0.0382 |
| Dividend per share | 107.14%0.0725 | 0.05 | -16.67%0.025 | 63.64%0.09 | 0.025 | 16.67%0.035 | 0 | 20.00%0.03 | -21.43%0.055 | 0 |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.